New Research: Injectable Dermal Matrix as a Skin Booster

A 2026 trial from Korea tested an injectable made from processed, donated human skin tissue as a "skin booster" for rough cheek skin. Over 20 weeks, the side of the face that received it showed more measured improvement in texture, density and pores than the side treated with a standard hyaluronic acid booster. It is an interesting early result from a small study, but this product is experimental, and its availability and Health Canada authorization status are unclear.

Why this was studied

Skin boosters are injections placed in many small amounts within the skin to improve how it looks and feels, rather than to add shape. Most are based on thin hyaluronic acid. Researchers are interested in whether other materials might do more than hydrate, for example by giving the skin a framework that encourages it to rebuild its own support structure.

An acellular dermal matrix is skin tissue from a human donor that has been processed to remove the cells, leaving behind the scaffold of collagen and other proteins. Surgeons have used sheet forms of this kind of material for years in reconstructive procedures. The idea being tested here is whether a finely particulated, injectable version could act as a booster. If you are new to the general concept, our article on skin booster injections explains how conventional boosters work.

What the researchers did

The trial enrolled 20 adults aged 30 to 65 (13 women and 7 men, average age about 55) who had moderately rough skin on the cheeks. Each person acted as their own comparison. One cheek received the dermal matrix product mixed with a small amount of non-cross-linked hyaluronic acid, a numbing agent and saline. The other cheek received a standard non-cross-linked hyaluronic acid booster. Neither the participants nor the assessors were told which side was which.

Participants were followed for 20 weeks. The team used imaging and skin instruments to track density, volume, moisture loss, hydration, pore size, elasticity, redness and pigmentation, along with clinician and participant ratings of overall improvement. The research group also ran laboratory work on donated skin samples, cell cultures and a small number of rats to look at how the material behaves in tissue.

What they found

Both sides improved on several measures, which is expected because both received an injectable booster. The dermal matrix side tended to improve more. By week 20, its average roughness score had dropped from about 2.9 to 1.9 on the study's scale, while the hyaluronic acid side barely changed. Ultrasound skin density, three-dimensional skin volume and pore area also improved more on the test side, and both clinicians and participants rated the test side as more improved overall.

In the laboratory work, the material spread evenly in the skin, and the researchers saw signs of new collagen forming around it in the animal tissue. These findings help explain a possible mechanism, but laboratory and animal results do not always carry over to people.

No serious side effects were reported. Some participants had mild, short-lived redness and swelling that settled on its own.

How strong is this evidence?

A randomized, blinded, split-face design is a thoughtful way to run a small trial, because it cancels out differences between people such as age, sun exposure and skincare habits. Still, there are important limits, several of which the authors acknowledge:

• Only 20 people took part, all at a single hospital, so the results may not apply to a wider or more diverse population.
• Twenty weeks is too short to know how long any benefit lasts or whether late reactions could appear.
• The test product also contained hyaluronic acid, which makes it harder to separate the effect of the matrix from its carrier.
• Many outcomes were measured without statistical adjustment for that, which raises the chance that some apparent differences are due to chance.
• Industry links: the test product was supplied by its manufacturer, and one author advised on developing it. That does not make the findings wrong, but independent studies would add confidence.

In short, this is early-stage evidence. It suggests a direction worth exploring, not an established treatment.

What it means for you

For now, this is research, not a treatment you should look for. Injectable dermal matrix boosters are not part of standard aesthetic practice in Canada, and whether any such product is authorized here can change over time. If you are curious about it, ask a physician whether it is authorized in Canada and appropriate for you. Because it is made from human donor tissue, questions about sourcing, screening and processing matter a great deal, which is one more reason never to seek it from unregulated online sellers, overseas clinics without clear oversight, or non-medical providers.

If rough texture, enlarged pores or thinning skin are your main concerns, there are well-studied options to discuss first. These include a consistent routine with sunscreen and a retinoid, conventional hyaluronic acid boosters, microneedling and certain laser treatments. Some people get a good result from skincare alone. Results vary from person to person, and a physician can help you match the approach to your skin type, health history and goals.

Questions to ask at your consultation

• What is causing the texture or pore changes I am noticing, and is there anything medical to rule out first?
• Which options for skin quality have the strongest evidence for someone with my skin type?
• Is a product approved by Health Canada for this use, and how can I check?
• What results are realistic, and how long would they be expected to last?

Frequently asked questions

Is a dermal matrix booster the same as filler?

No. Filler is designed to add volume or structure in a specific spot. A booster is spread through the skin to improve its quality. The product in this study is also made from a different material than the hyaluronic acid used in most fillers and boosters.

Does "made from human tissue" mean it is risky?

Donor-derived materials go through screening and processing designed to make them safe, and this study reported only mild, temporary reactions. However, 20 people over 20 weeks is far too few to judge rare or delayed risks. That is exactly why larger, longer studies and regulatory review are needed.

Should I wait for this instead of trying something now?

There is no reason to put off proven care while waiting for an experimental product that may or may not become available. Sun protection and a sound routine help skin at any age, and a physician can explain which established treatments, if any, make sense for you.

Early research like this is a reminder that skin-quality treatments are still evolving. If you would like to talk through the options that are available and appropriate for you, HealthPark Medical Aesthetics is happy to review them with you at a consultation.

Source

Lee YI, Chau NH, Nguyen NH, Ham S, Baek Y, Kim J, Lee JH. Injectable particulated human acellular dermal matrix booster for skin restoration: an integrated randomized, split-face, double-blinded clinical trial and preclinical study. International Journal of Molecular Sciences, 2026. Read the study